Simcere Pharmaceutical Posts 2.6% Profit Increase in 2024; EPS, Revenue Miss Estimates; Shares Down 3%

MT Newswires Live
03-25

Simcere Pharmaceutical Group (HKG:2096) reported a 2.6% increase in profit attributable to equity shareholders for 2024 to 733.2 million yuan, from 714.8 million yuan in the previous year, according to a filing with the Hong Kong bourse on Monday.

Earnings per share grew to 0.29 yuan from 0.27 yuan a year ago. Analysts polled by Visible Alpha estimated EPS at 0.35 yuan.

Revenue for the year increased marginally by 0.4% to 6.64 billion yuan, from 6.61 billion yuan in the prior year. Analysts polled by Visible Alpha estimated revenue at 6.71 billion yuan.

The board declared a final dividend of 0.16 yuan per share, subject to shareholders' approval. The final dividend is expected to be paid on or before July 14 to shareholders on record as of June 24.

The company's shares were down nearly 3% in recent trading.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10